The companies will perform tumor profiling to identify patients with genetic abnormalities that could make them eligible for treatment in the NCI study.
There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
Caris will be on the lookout for pancreatic cancer patients with low DNA mismatch repair protein expression.
There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.
The assay will be designed to predict how pancreatic cancer patients respond to Threshold's investigational drug evofosfamide.
Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.
COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.
Syapse is using the Series C funding to hire new staff and extend its Syapse Precision Medicine platform to support disease areas beyond cancer.
Members of Caris' Centers of Excellence for Precision Medicine Network will use the Syapse Precision Medicine Platform to merge data sets.
The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.
An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.
The US Department of Agriculture presents a new blueprint for animal genomic research.
In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.